Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Leukemia. 2018 Oct;32(10):2095-2104. doi: 10.1038/s41375-018-0247-1. Epub 2018 Sep 10.
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). Although these treatments have changed the natural course of CML and many other cancers, they may cause cardiovascular and/or metabolic complications. In this review, we discuss how overlooking the main drivers of cardiovascular events (CVEs) and lack of standard definitions for cardiovascular adverse events might have affected these event rates in CML trials. Methodological limitations that affect the available data are discussed, with an emphasis on the future direction of cardiovascular safety research in trials of investigational drugs in cancer treatment.
酪氨酸激酶抑制剂 (TKI) 彻底改变了慢性髓性白血病 (CML) 的治疗方法。尽管这些治疗方法改变了 CML 和许多其他癌症的自然病程，但它们可能会引起心血管和/或代谢并发症。在这篇综述中，我们讨论了忽视心血管事件 (CVE) 的主要驱动因素以及缺乏心血管不良事件的标准定义如何影响 CML 试验中的这些事件发生率。讨论了影响可用数据的方法学限制，并强调了在癌症治疗中研究药物试验的心血管安全性研究的未来方向。
